gastrin releasing peptide, human

Gastrin-Releasing Peptide, human(TFA) is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Gastrin-Releasing Peptide, human is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Human growth hormone-releasing factor acetate is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary[1].

[Leu15]-Gastrin I human acetate(39024-57-2 Free base) is a useful organic compound for research related to life sciences and the catalog number is T8761L.

C-Type Natriuretic Peptide (CNP) (1-22), human acetate is an agonist of natriuretic peptide receptor B (NPR-B), an endothelial-derived relaxant and growth inhibitory factor. C-Type Natriuretic Peptide (CNP) (1-22), human acetate inhibits cAMP synthesis stimulated by histamine and 5-HT or directly by Forskolin.

Gastrin I (1-14), human, represents the 1-14 peptide fragment of human gastrin I, an endogenous gastrointestinal peptide hormone. This compound is the principal hormonal regulator of gastric acid secretion.

Amyloid β Peptide (42-1)(human) acetate is the inactive form of Amyloid β Peptide (1-42). Amyloid β Peptide (42-1)(human) acetate is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

GnRH Associated Peptide (GAP) (1-13), human Acetate was found to be a potent inhibitor of prolactin secretion and to stimulate the release of gonadotropins. Active immunization with peptides corresponding to GAP sequences led to greatly increased prolacti

Proinsulin C-peptide human acetate (Proinsulin C-peptide human acetate (33017-11-7 Free base)) is a polypeptide of 31 amino acid residues that links the A and B chains of proinsulin to ensure proper folding, has biological activity and regulates cellular functions.

Gastrin I (human) acetate (Gastrin-17 acetate) is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

Peptide YY (PYY) (3-36), human (Peptide YY (3-36)) is a gut hormone peptide. Peptide YY (PYY) (3-36), human acts as a Y2 receptor agonist to reduce appetite.

Corticotropin-releasing factor (human) acetate stimulates to synthesize and secret adrenocorticotropin in the anterior pituitary.

Mini Gastrin I, human acetate is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide.

Pegylated synthetic human C-peptide exhibits similar bioactivity to natural C-peptides (non-polyethylene glycolated) and demonstrates an extended plasma half-life, making it suitable for research in diabetic peripheral neuropathy [1].

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not en

Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that acts to release ACTH from the anterior pituitary and stimulates the sympathetic nervous system and adrenal medulla. Functions b

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) that exerts endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide holds promise for cardiovascular diseases research.

Klotho-derived peptide 1 (KP1) (56-87), a peptide originating from the human Klotho protein, disrupts TGF-β signaling by binding to TGF-β receptor types 1 and 2 (TGFBR1 and TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 at a concentration of 10 µg/ml hinders the TGF-β-induced escalation of fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. Furthermore, in vivo studies reveal that KP1, administered at 1 mg/kg per day, preferentially accumulates in damaged kidneys, leading to significant reductions in serum creatinine and blood urea nitrogen levels, indicators of improved kidney function. Additionally, it decreases kidney fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.

Prolactin-Releasing Peptide (12-31), rat, a fragment of PrRP, exhibits high affinity for GPR10 receptors and stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor [1] [2].

Mini Gastrin I, human, is a truncated form of the human gastrin peptide, encompassing amino acids 5-17 of the original sequence.

Proinsulin C-peptide (human) is a 31-amino acid peptide that connects the Proinsulin a and B chains, ensuring its proper folding, biological activity, and regulation of cellular functions.

Human CRF acetate is a chemical compound that effectively stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

Prolactin-Releasing Peptide (1-31) (rat) serves as a ligand for the UHR-1/GRP10 receptor, moderating fasting-induced food intake and elevating plasma concentrations of LH, FSH, and testosterone in rats [1] [2].

Human Follicular Gonadotropin Releasing Peptide (hF-GRP) is a hormonal peptide that, in vitro, can induce the secretion of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] [2].

Experimental allergic encephalitogenic peptide (human), an EAE peptide, induces encephalomyelitis in guinea pigs [1].

Human growth hormone-releasing factor stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary.Growth hormone-releasing hormone is a hormone produced in the hypothalamus. The main role of growth hormo

Glucagon-like peptide 1 (1-37), human acetate is a highly potent the GLP-1 receptor agonist.

Peptide YY (PYY), a novel 36 amino-acid amidated hormone is a component of the complex neuroendocrine control process.Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.

Growth hormone releasing peptide ia a natual product ,and has anti-inflammatory effects, due to its inhibitory effect on PKC-induced activation of p38, JNK and NF-κB, possibly by targeting to MKP-1 and PP2A.

Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin

(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1].

Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)), a peptide hormone produced by the atrial myocardium, plays a critical role in the regulation of blood pressure, fluid balance, and electrolyte homeostasis [1] [2].

Myelin oligodendrocyte glycoprotein (MOG) peptide, a truncated form of MOG located on the extracellular myelin sheath surface, interacts with antigen serotype HLA-DR2 to mitigate effects of ischemic stroke induced by middle cerebral artery occlusion (MCAO) in mice. In female mice, it notably reduces cortical and striatal infarct volumes, lessens sensorimotor deficits as observed in tube- and corner turn tests, enhances engagement with novel odors, and prolongs the duration of cage mate-directed vocalizations, without exhibiting similar outcomes in male mice.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY, acting as a potent and selective Y1 receptor agonist with a dissociation constant (KD) of 1.0 nM [1].

Human Growth Hormone-Releasing Factor TFA, also known as Growth Hormone-Releasing Factor Human TFA, is a hypothalamic polypeptide that promotes the production and release of growth hormone (GH) through its interaction with the Growth Hormone-Releasing Hormone Receptor (GHRHR) on anterior pituitary cells [1].

CNP, a member of the natriuretic peptide family, was first identified in porcine brain and later found in other mammals as well as non-mammals. Processing of the CNP precursor gives rise to CNP-22 and its N-terminally elongated form, CNP-53. The CNPs shar

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.

Amyloid-β (25-35) (Aβ (25-35)) is an 11-residue fragment of the Aβ protein that retains the physical and biological characteristics of the full length peptide. It forms fibrils that react to thioflavin T and Congo red and are organized in a cross-β arrangement of β-strands similar to Aβ (1-40) and Aβ (1-42) fibrils. Aggregated Aβ (25-35) decreases the viability of rat adrenal PC12 cells. It also decreases the viability of primary rat cortical neurons at concentrations ranging from 1 nM to 30 μM. In vivo, intracerebral injection of Aβ (25-35) (20 nmol) in rats induces lesions of neuronal and tissue loss. Aggregated Aβ (25-35) administered intracerebroventricularly to rats induces learning and memory impairments in the Y-maze, novel object recognition, and contextual fear conditioning tests.

Gastrin I, human (Gastrin I (human)) is an endogenous peptide produced in the stomach that increases pepsinogen and acid secretion via the CCK2 receptor in the rat.

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].

Galanin-Like Peptide (human) is a neuropeptide consisting of 60 amino acids, instrumental in regulating feeding, body weight, and energy metabolism [1].

Peptide YY (PYY) (3-36), human trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64716.

This human neuropeptide of the RFamide peptide family with orexigenic activity may be also involved in the control of feeding behavior. The 26RFa gene is exclusively expressed in the ventromedial hypothalamic nucleus and in the lateral hypothalamic area.

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide that has been biotinylated at the C-terminal.

Mini Gastrin I, human (TFA) is a truncated form of the human gastrin peptide, encompassing amino acids 5-17 of the original sequence.

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po

Peptide YY (PYY) (3-36), human (TFA) is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite[1].